Pfizer exec makes an abrupt exit; Boehringer's Pradaxa beats warfarin in clotting;

@FierceBiotech: Biogen Idec preps for a big leap into the anti-TNF blockbuster biosimilars market. More | Follow @FierceBiotech

@JohnCFierce: "Amy Schulman and Pfizer have agreed to separate." What, no retirement? More | Follow @JohnCFierce

@DamianFierce:  Amgen keeps with the PCSK9 pack in its first Phase III results for evolocumab. News | Follow @DamianFierce

@EmilyMFierce: Researchers find a possible drug target for undruggable melanoma. Story | Follow @EmilyMFierce

> Boehringer Ingelheim's Pradaxa proved just as effective as warfarin in preventing blood clots, giving the company hope of winning a broader indication for the drug. News

> Pfizer's ($PFE) Amy Schulman is no longer with the company, a surprise departure revealed just weeks before she was meant to take the helm of the company's vaccines, oncology and consumer healthcare business. Article

> Researchers at Vanderbilt University have discovered some promising drug targets for hard-to-treat melanomas previously considered undruggable. More

Medical Device News

@FierceMedDev: TruTouch Technologies (biometric alcohol sensor) names Marathon's Bruce Berger CEO. Release | Follow @FierceMedDev

@MarkHFierce: In an interesting twist, ViewRay's new $30M round includes an investment from a Chinese distributor. Story | Follow @MarkHFierce

@MichaelGFierce: Alnylam begins PhII trial for amyloidosis RNAi treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Boston Scientific recruits a veteran Silicon Valley investor amid its M&A push. More | Follow @GalenMoore

> Belgium's Cardio3 Biosciences gets $5.5M to advance heart catheter, stem cell treatment. Item

> SynCardia's $14M infusion will fuel formal testing of a smaller-sized heart implant. Story

Pharma News

@FiercePharma: Whoa: Amy Schulman is out, rather abruptly, at Pfizer. She was one of the three division chiefs chosen by CEO Ian Read earlier this year. | Follow @FiercePharma

@EricPFierce: Teva renegs on plans to build a new API plant in India. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business. Release | Follow @CarlyHFierce

> Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout. Story

> Traders bet Novartis CEO will bail out of its $14B Roche stake. More

> Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit. News

> GlaxoSmithKline scraps doc payments, sales-rep quotas in global marketing revamp. Article

> Supreme Court won't take up ex-InterMune CEO's free-speech defense. Report

> Chinese whistleblower tags Shanghai Pharma with bribery allegations. Item

Pharma Manufacturing News

> China rounds up hundreds in crackdown against drug counterfeiters. More

> Novartis' OTC recall is tied to a contractor this time. Story

> Novartis to shed Alcon plant, 300 jobs next year. News

> What's a makeover cost these days? For AstraZeneca's distribution hub, $100M. Article

> Teva reneges on its proposal to build a $141M API plant in India. Report

> Wales fines companies £120,000 for worker accidents. Item

Biotech Research News

> Congressional budget deal would ease NIH sequester cuts. Story

> Report: Life science research needs standards to curb irreproducible studies. More

> CIRM awards $61M for cancer research. Item

> Researchers find possible drug targets for undruggable melanomas. News

> Blood vessel breakdown in the brain may be linked to Alzheimer's. Report

Glaxo compound slows Lou Gehrig's disease in animal models. Article

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.